ResMed Inc. (NYSE:RMD) Plans $0.60 Quarterly Dividend

ResMed Inc. (NYSE:RMD) declared a quarterly dividend on Thursday, January 29th. Stockholders of record on Thursday, February 12th will be paid a dividend of 0.60 per share by the medical equipment provider on Thursday, March 19th. This represents a c) annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, February 12th.

ResMed has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 13 consecutive years. ResMed has a dividend payout ratio of 22.7% meaning its dividend is sufficiently covered by earnings. Equities analysts expect ResMed to earn $10.36 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 23.2%.

ResMed Price Performance

ResMed stock traded down $5.36 during trading on Friday, reaching $252.25. The company had a trading volume of 580,205 shares, compared to its average volume of 931,231. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89. The firm’s 50-day simple moving average is $250.90 and its 200 day simple moving average is $263.20. The firm has a market capitalization of $36.81 billion, a PE ratio of 26.15, a price-to-earnings-growth ratio of 1.73 and a beta of 0.88. ResMed has a 1-year low of $199.92 and a 1-year high of $293.81.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.13. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.40 billion. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.43 earnings per share. As a group, equities research analysts anticipate that ResMed will post 9.47 earnings per share for the current fiscal year.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat expectations — ResMed reported revenue of $1.423B (up 11% yoy) and non‑GAAP EPS of $2.81, topping Street estimates; management cited strong demand for sleep and respiratory devices which drove margin expansion. Article Title
• Positive Sentiment: Dividend and buybacks — Board declared a $0.60 quarterly cash dividend (record Feb 12, payable Mar 19) and repurchased $175M of stock in the quarter, supporting yield and shareholder returns. Article Title
• Positive Sentiment: Margin and cash-flow improvement — Gross margin rose ~320 bps to 61.8%; operating cash flow was $340M, and non‑GAAP operating income grew ~19%, indicating improved profitability and operational leverage. Article Title
• Neutral Sentiment: Product & regulatory update — Company received FDA clearance for an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings; promising long‑term for adherence but commercial impact will accrue over time. Article Title
• Neutral Sentiment: Analyst backdrop — Multiple buy/overweight ratings and a median 6‑month price target near $300 signal continued analyst support; useful context but not new catalyst. Article Title
• Negative Sentiment: Rising operating costs and one‑time charges — SG&A and R&D increased (SG&A up ~12% on constant currency) and ResMed recorded $6M restructuring charges; SG&A as a percent of revenue ticked higher which could pressure margins if spending continues. Article Title
• Negative Sentiment: Insider selling — Recent filings show multiple insider sales (no purchases) over past six months; while not unusual at large caps, heavy insider selling can be viewed negatively by some investors. Article Title

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.